nk 611 has been researched along with Neutropenia in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cavalli, F; D'Incalci, M; De Fusco, M; de Jong, J; Hanauske, A; Kaeser-Fröhlich, A; Pagani, O; Sessa, C; Zucchetti, M | 1 |
| Hanauske, AR; Kaeser-Fröhlich, A; Rassmann, I; Rastetter, J; Schilling, T; Schrödel, H; Zucchetti, M | 1 |
2 trial(s) available for nk 611 and Neutropenia
| Article | Year |
|---|---|
Clinical and pharmacokinetic study of oral NK611, a new podophyllotoxin derivative.
Topics: Administration, Oral; Adrenal Gland Neoplasms; Adult; Aged; Antineoplastic Agents; Area Under Curve; Biological Availability; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Disease Progression; Drug Administration Schedule; Female; Humans; Injections, Intravenous; Lung Neoplasms; Male; Middle Aged; Neoplasms; Neutropenia; Podophyllotoxin; Thrombocytopenia | 1996 |
Clinical and pharmacokinetic phase I trial of oral dimethylaminoetoposide (NK611) administered for 21 days every 35 days.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Cell Count; Drug Administration Schedule; Female; Humans; Leukopenia; Male; Middle Aged; Neoplasms; Neutropenia; Podophyllotoxin | 1996 |